United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.

United Therapeutics: Economics Support Compounding Ability

Axon Enterprise

Halozyme Therapeutics

The stock market's bearish reversal left its rebound in doubt but a rally attempt remains in play.

Stock Market Fades Badly As Dow Jones Index Turns Back At This Critical Level

Vertex Pharmaceuticals

The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.

3 Biotech Stocks on Track for 50% Returns (or More) by 2028

Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?

Zoetis

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

UTHR or ZTS: Which Is the Better Value Stock Right Now?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

United Therapeutics (UTHR) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR)

United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Roanna Ruiz - Leerink Partners Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Andreas Argyrides – Oppenheimer Operator Good morning, everyone and welcome to the United Therapeutics Corporation Second Quarter 2024 Earnings Webcast. My name is Cole and I will be your conference operator today.

United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Transcript

United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

United Therapeutics reported better-than-expected second-quarter sales, but earnings widely missed and shares tumbled.

United Therapeutics Stock Skids On Mixed Second-Quarter Results

United Therapeutics (UTHR) came out with quarterly earnings of $5.85 per share, missing the Zacks Consensus Estimate of $6.33 per share. This compares to earnings of $5.24 per share a year ago.

United Therapeutics (UTHR) Misses Q2 Earnings Estimates

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023. “This quarter we drove record revenue from our foundational commercial business. Next year we expect data from our innovative.

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

3D Systems

Investing in 3D bioprinting stocks is a highly speculative and specialized approach to the biotech industry in general. That's because it blends two relatively niche technologies to create a broader application that may be part of the future of surgery and medical treatments.

The 3 Best 3D Bioprinting Stocks to Buy Now

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 31, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via Unit.

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

Exact Sciences

Sarepta Therapeutics

In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

3 Biotech Stocks You Should Know About

Catalent

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

UTHR vs. CTLT: Which Stock Is the Better Value Option?

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?

UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?

ABB Ltd

Banco de Chile

Lockheed Martin

MPLX

United Therapeutics (UTHR), ABB (ABBNY), Lockheed Martin (LMT), MPLX (MPLX) and Banco de Chile (BCH) are some of the stocks with high ROE to profit from as easing inflationary pressures ignite rate cut hopes.

5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes

Amgen

Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals.

3 Biotech Stocks to Buy Now: Q3 Edition

United Therapeutics (UTHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for United Therapeutics Stock (UTHR)